Sana Biotechnology Inc News - SANA | ADVFN

S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

Home
Investing
Stocks
USA
NASDAQ
Sana Biotechnology Inc (SANA)
Sana Biotechnology Inc (SANA) News

Sana Biotechnology Inc (SANA)

2.42

0.00

(0.00%)

Closed 18 November 8:00AM

Delayed by 15 minutes

0.00

0.00

(0.00%)

After Hours: -

Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates

Continue to advance hypoimmune technology in three trials across five indications in type 1 diabetes, B-cell...

Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025

Prioritize clinical and preclinical development on type 1 diabetes (UP421 and SC451), B-cell mediated...

Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence

Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and...

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors

Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors PR Newswire CAMBRIDGE, Mass...

Sana Biotechnology to Present at the Goldman Sachs Cell Therapy Day Conference

SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on...

Form 8-K - Current report

Sana Biotechnology to Present at September 2024 Investor Conferences

SEATTLE, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on...

Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer

SEATTLE, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Sana Biotechnology Reports Second Quarter 2024 Financial Results and Business Updates

Continue to advance hypoimmune technology in four trials across seven indications in oncology, B-cell mediated...

1
Next

Monksdream

Monksdream 4 weeks ago

Monksdream

Monksdream 2 months ago

Monksdream

Monksdream 4 months ago

Monksdream

Monksdream 4 months ago

Monksdream

Monksdream 9 months ago

SANA new 52 week high

Monksdream

Monksdream 10 months ago

SANA up from a low in November

Moneymaker77777

Moneymaker77777 2 years ago

https://www.globenewswire.com/news-release/2023/03/16/2629176/0/en/Sana-Biotechnology-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Business-Updates.html

Sana Biotechnology

Bank of Montreal

Lancaster Colony

Norwood Financial

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions